For the first time, Chinese drugmakers have won more approvals for cancer drugs than their foreign peers, but drug development is too concentrated in oncology and certain targets, regulators said at two recent conferences.
Chinese drug regulators are making it clear that pediatric drug development is at the top of its agenda with a slew of new regulations.
China's latest insulin volume-based procurement is poised to change the market value of insulin, paving way for domestic insulin products to enter large hospitals.
China’s NHSA and NHC jointly issued a document calling on regulatory bodies at the local level to normalize NRDL negotiation drugs and to ensure that these meet their clinical needs.
The new law, set to take effect March 1, 2022, will grant physicians the right to use off-label drugs that could benefit drugmakers.
Both events marks the official implementation of China's drug patent linkage system.
The COVID-19 Pandemic Sparks New Healthcare Reform Measures in China.